Vir Biotechnology, Inc. filed a Form 8-K on November 13, 2026, disclosing an underwriting agreement dated November 12, 2026, for a public offering of 15,000,000 shares of common stock at $10.00 per share, with an expected closing date of November 16, 2026.

Key Highlights

  • Offering size: 15,000,000 shares of common stock offered at $10.00 per share to the public.
  • Expected net proceeds: Approximately $140.4 million, after underwriting discounts, commissions, and estimated offering expenses.
  • Overallotment option: Underwriters were granted a 30-day option to purchase up to an additional 2,250,000 shares at the public offering price.
  • Full option proceeds: If the overallotment option is exercised in full, net proceeds would increase to approximately $161.5 million, according to the filing.
  • Lead underwriters: Leerink Partners LLC, Morgan Stanley & Co. LLC, and Evercore Group L.L.C. serve as representatives of the underwriters.
  • Registration: Shares are being offered under an effective Form S-3ASR registration statement filed November 12, 2026 (File No. 333-299995), with a prospectus supplement dated the same date.

Vir Biotechnology's November 2026 Common Stock Offering Details

According to the filing, Vir Biotechnology, Inc. (trading on the Nasdaq Global Select Market as NASDAQ:VIR) entered into an underwriting agreement on November 12, 2026, with Leerink Partners LLC, Morgan Stanley & Co. LLC, and Evercore Group L.L.C. as representatives of the several underwriters. The agreement covers the offer and sale of 15,000,000 shares of Vir Biotechnology common stock, par value $0.0001 per share, at a public offering price of $10.00 per share. The filing states the offering was expected to close on November 16, 2026, subject to customary closing conditions.

The company disclosed that it expects to receive net proceeds of approximately $140.4 million from the offering after deducting underwriting discounts and commissions and estimated offering expenses. The underwriters were also granted an option, exercisable for 30 days, to purchase up to an additional 2,250,000 shares at the public offering price. The filing notes that if this option is exercised in full, net proceeds would reach approximately $161.5 million.

The filing states that the underwriting agreement contains "customary representations, warranties and covenants by Vir Bio, customary conditions to closing and indemnification obligations of Vir Bio and the Underwriters against certain liabilities." The shares are offered pursuant to an effective registration statement on Form S-3ASR, including a base prospectus filed with the SEC on November 12, 2026 (File No. 333-299995), and a prospectus supplement dated November 12, 2026. The filing was signed by Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, on November 13, 2026.

What Was Disclosed

Vir Biotechnology disclosed the terms of an underwriting agreement for a 15,000,000-share public stock offering at $10.00 per share, with anticipated net proceeds of approximately $140.4 million, and an overallotment option for up to 2,250,000 additional shares.